Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 9/20 | 0.46 |
| ▸ | PKLR | P30613 | 7/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426957 | 0.78 | PSEN1 (0.47) | ALDH1A1GAAKAT6AMAPT | |
| SCHEMBL8224040 | 0.74 | CA1 (0.54) | PKMPKLRSLC40A1HPGD | |
| SCHEMBL420075 | 0.74 | PKM (0.49) | PKMPKLRSLC40A1BRD4KDM4E | |
| SCHEMBL15116336 | 0.74 | PKM (0.49) | PKMPKLRSLC40A1BRD4ALDH1A1 | |
| SCHEMBL424802 | 0.71 | PKM (0.46) | PKMPKLRSLC40A1BRD4ALDH1A1 | |
| SCHEMBL7595736 | 0.71 | SLC40A1 (0.61) | PKMSLC40A1BRD4PTGES2 | |
| SCHEMBL426036 | 0.71 | PSEN1 (0.49) | ALDH1A1GAAKAT6ALMNA | |
| SCHEMBL24429357 | 0.69 | MAPT (0.50) | PKMPKLRSLC40A1ALDH1A1KDM4E | |
| SCHEMBL7579145 | 0.69 | PKM (0.83) | PKMSLC40A1ALDH1A1 | |
| SCHEMBL22145982 | 0.69 | SLC40A1 (0.59) | PKMSLC40A1BRD4ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233645-A1 | EFFECTIVE TREATMENTS FOR VASCULAR ASSOCIATED MACULOPATHY, SEVERE MACULOPATHY, LATE-STAGE MACULOPATHY, AND ABERRANT CHORIOCAPILLARIS | UNIV UTAH RES FOUND (US) | 2023-07-27 | — | — | US | disclosed |
| EP-4185301-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIGH GRADE SUBTYPES OF UTERINE CANCER | The Regents Of The University Of Michigan (US) | 2023-05-31 | — | — | EP | disclosed |
| US-11371993-B2 | Autoantibody biomarkers of ovarian cancer | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2022-06-28 | — | — | US | disclosed |
| US-11255857-B2 | Biomarkers for ovarian cancer CTAP3-related proteins | ASPIRA WOMEN'S HEALTH INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220049315-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIGH GRADE SUBTYPES OF UTERINE CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-02-17 | — | — | US | disclosed |
| US-20210353712-A1 | METHODS OF DIAGNOSING AND TREATING VASCULAR ASSOCIATED MACULOPATHY AND SYMPTOMS THEREOF | UNIV UTAH RES FOUND (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210181207-A1 | Biomarkers for Ovarian Cancer: B2 Microglobulin | ASPIRA WOMEN'S HEALTH INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20200237861-A1 | METHODS OF DIAGNOSING AND TREATING VASCULAR ASSOCIATED MACULOPATHY AND SYMPTOMS THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2020-07-30 | — | — | US | disclosed |
| EP-2805167-B1 | BIOMARKERS FOR GASTRIC CANCER AND USES THEREOF | Adelaide res & innovation pty ltd (AU) | 2020-04-22 | — | — | EP | disclosed |
| US-20190285637-A1 | BIOMARKERS FOR GASTRIC CANCER AND USES THEREOF | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2019-09-19 | — | — | US | disclosed |
| WO-2005121758-A1 | BIOMARKERS FOR PERIPHERAL ARTERY DISEASE | CIPHERGEN BIOSYSTEMS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050260691-A1 | Serum biomarkers for Chagas disease | CIPHERGEN BIOSYSTEMS, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005103281-A2 | PLATELET BIOMARKERS FOR THE DETECTION OF DISEASE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050244890-A1 | Biomarkers for Alzheimer's disease | VERMILLION, INC. (F/K/A CIPHERGEN BIOSYSTEMS, INC.) | 2005-11-03 | — | — | US | disclosed |
| US-20050181398-A1 | Specific detection of host response protein clusters | CIPHERGEN BIOSYSTEMS, INC. | 2005-08-18 | — | — | US | disclosed |
| WO-2005055812-A2 | SERUM BIOMARKERS FOR CHAGAS DISEASE | CIPHERGEN BIOSYSTEMS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005047484-A2 | BIOMARKERS FOR ALZHEIMER'S DISEASE | CIPHERGEN BIOSYSTEMS, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005043111-A2 | SERUM BIOMARKERS FOR SARS | CIPHERGEN BIOSYSTEMS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050064511-A1 | Polypeptides related to natriuretic peptides and methods of their identification and use | CIPHERGEN BIOSYSTEMS, INC. (US) | 2005-03-24 | — | — | US | disclosed |
| WO-2004094460-A2 | POLYPEPTIDES RELATED TO NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE | CIPHERGEN BIOSYSTEMS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |